The complexities, intricacies and nuances of oncology trials require an intimate understanding of specific malignancies. That’s why our oncology division is organized into two subgroups: one specializing in solid tumors and the other focused on hematology oncology. We have the indication-specific oncology experience to effectively guide your drug through trial.

With staff throughout North America, Europe and Asia, we have experience in more than 50 countries, currently with active trials in 46 countries.

Oncology Experience

Early to Mid-Phase

With more than 325 early and mid-phase studies and long-standing relationships with Phase I sites, we’re able to make timely, well-informed decisions regarding cohort enrollment and dose escalations. That customization enables us to monitor the intricacies in data, safety and the lab to act quickly in treating critically ill subjects. And our global capabilities allow for international expansion to support multi-arm randomized, stratified trials.

Late Phase

With oncology experience in implementing more than 80 Phase III and IV trials, as well as our fully integrated eClinical infrastructure, we’re able to streamline huge amounts of data with full transparent access. Our global reach and ISO 9001:2008 certification ensures your quality goals are met. Additionally, our medical and clinical staff is comprised of board-certified hematologists, oncologists and a CSO with more than 40 years of research and industry experience. In fact, we’ve supported five FDA-approved oncology products in the past three years alone.

Together we’re advancing trials and improving lives.








Infographic Sources:
1. “The Global Use of Medicines: Outlook Through 2015,” Report by the IMS Institute for Healthcare Informatics. May 2011.
2. “New Frontiers in Focus,” Michael D. Christel, R&D Directions. October 2010.
3., Accessed June 29, 2012
4. GLOBOCAN 2008, International Agency for Research on Cancer, WHO 5. Research!America. Research Enterprise Survey. Accessed December 27, 2010